ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN

Similar documents
Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

EAU GUIDELINES ON MALE HYPOGONADISM

EAU GUIDELINES ON MALE HYPOGONADISM

GUIDELINES ON MALE HYPOGONADISM

6/14/2010. GnRH=Gonadotropin-Releasing Hormone.

Late onset hypogonadism

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients

Testosterone Therapy in Men with Hypogonadism

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands

Testosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E

Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang

Prior Authorization Criteria Update: Androgens, Topical and Parenteral

Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men

Male History, Clinical Examination and Testing

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA

TESTOSTERONE DEFINITION

Consent for Testosterone Therapy-Men Revised 4/10/18

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital

Male Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo

How to treat: TRT modalities and formulations

ANDROGEN DEFICIENCY/MALE HYPOGONADISM

Low Testosterone Consultation Information

Testosterone Injection / Implant

Board Review with The Chiefs. October 17, 2016 October 23, 2016

OVERVIEW OF PRESENTATION

A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes

The Sexual Medicine Society of North. Adult-Onset Hypogonadism SPECIAL ARTICLE

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description

Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University

Testosterone Injection and Implant

ANDROGEN DEFICIENCY/MALE HYPOGONADISM

Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None

BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE

Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)

Prescribing Guidelines

Testosterone Injection and Implant

Assessment and management of male androgen disorders: an update

What Is the Low T Syndrome? Is Testosterone Supplementation Safe?

Testosterone Injection and Implant

Laboratory Investigation of Male Gonadal Function. Dr N Oosthuizen Dept of Chemical Pathology UP 2010

Where are the injections given? They are given in the upper outer hip.

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline

Therapeutic Use Exemptions

DEFINITION HX & PH/EX

Male New Patient Package

Contents. At A Glance 04. Male Hormones 06. Androgen Deficiency 10. Symptoms 11. Causes 14. Staying Healthy 20. Diagnosis 22. Treatment 29.

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

GA KS KY LA MD NJ NV NY TN TX WA Applicable X X N/A N/A X N/A X X X X X X N/A N/A NA *FHK- Florida Healthy Kids. Androgens

Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany

GP guide to testosterone replacement therapy in men

Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline

Clinical evaluation of infertility

Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)

Hypogonadism and Testosterone Replacement Therapy: Pharmacist

Quick Reference Guide to PE

Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes:

Prescribing Framework for Testosterone in Adults

What You Need to Know

Testosterone and PDE5 inhibitors in the aging male

Male Patient Questionnaire & History

43 year old man with low libido. Katie Stanley, MD August 16, 2012

Point-Counterpoint: Late Onset Hypogonadism (LOH)

EAU Guidelines on Male Hypogonadism

Recognizing and Managing Testosterone Deficiency

An Update on Men s Health and Sexual Function

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency

Male New Patient Questionnaire

HORMONE BALANCE QUESTIONNAIRE FOR MEN

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male

Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018

The CATCH checklist to investigate adult-onset hypogonadism

ANDROGEN DEFICIENCY Update on Evaluation and Management

in Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University

AQUA Registry 2019 Non-QPP Measure Specifications. Denominator Exceptions. IPSS<8 None None Yes Patient Reported Outcome (PRO)

Testosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder

Retrospective Study of Klinefelter Syndrome in Chinese Boys

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:

Testosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder

ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM

Advisory Committee Industry Briefing Document. Testosterone Replacement Therapy

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5)

Basics of Male Libido: Dysfunction & Treatment. Ripu Hundal MD FACE First State Endocrinology Newark, DE

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase

Men s Health Hormone Self-Assessment

Implantable Hormone Pellets

The Centre for Men s Health

GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA. Information for Primary Care December 2015 (Review Date June 2016)

Transcription:

International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015

What is testosterone deficiency? Testosterone deficiency (TD) is a clinical and biochemical syndrome characterized by a deficiency of testosterone, or testosterone action, and relevant symptoms and signs. To make a diagnosis of TD, affected men must have symptoms of TD. TD affects 2-6% of adult men, and may affect the function of multiple organ systems. TD may result in significant detriment in the quality of life due to alterations in sexual function, cardiovascular risk, glycemic control, bone health, and many other aspects of men s health. AND To make a diagnosis of TD, affected men must have a serum total testosterone that is consistently <8 nmol/l (231 ng/dl). BUT Men with a serum total testosterone that is consistently >8 nmol/l (231 ng/dl) but 12nmol/L (346ng/dL) may have TD and may be offered a trial of testosterone replacement therapy (TRT); a sustained improvement in symptoms over a period of six months in response to TRT would confirm the diagnosis. What causes TD? Reduced testicular synthesis of testosterone due to impaired Leydig cell function (primary hypogonadism) Reduced testicular synthesis of testosterone due to inadequate gonadotropic stimulation of Leydig cells (secondary hypogonadism) Medical conditions that may cause TD include: Primary TD: Klinefelter s syndrome, Noonan syndrome; testicular infarction; hemochromatosis; some drugs and surgeries; previous cryptorchidism, mumps orchitis, testicular trauma, torsion or irradiation. Secondary TD: isolated hypogonadotropic hypogonadism; Kallmann s syndrome; Prader-Willi syndrome; Pasqualini s syndrome; primary and secondary CNS tumours; diabetes; obesity; hyperprolactinemia; some drugs; hypothalamicpituitary irradiation or surgery. TD always has a cause; this should be identified and documented, and reversible causes should be effectively treated. 2 ISSM Quick Reference Guide on Testosterone Deficiency for men

Clinical history In most men, symptoms are quite variable and onset is frequently very gradual. Common symptoms include: reduced muscle strength; physical frailty; impaired concentration; impaired verbal memory; fatigue; tendency to fall asleep during the day; insomnia; reduced sense of general well-being; reduced energy and motivation; anxiety; depression; irritability; reduced sexual desire; infrequent or absent nocturnal erections and erections on wakening; impaired erectile, ejaculatory and orgasmic function. Currently available questionnaire instruments for the assessment of TD lack adequate specificity and their use is not recommended. Physical examination and signs Many men with TD have normal physical examination findings. Physical signs of the various health problems associated with TD may be present, particularly obesity. The following findings should be documented: assessment of general body habitus, including breast development (evidence of gynecomastia); nutritional state (height, weight, BMI, waist circumference); muscle development and strength; hair growth (body and facial hair; androgenic alopecia); inspection of the penis and testes to assess post-pubertal development; palpation of scrotal contents (evidence of testicular maldescent; size and consistency of testes and epididymes; evidence of scarring from previous infection/inflammation). Digital rectal examination is not essential for the initial assessment of TD but, in men over 40, it must be performed before any treatment for TD is commenced. Laboratory diagnosis Step 1: Total testosterone (TT) assay on serum from a venous blood sample drawn between 08:00AM and noon. If TT 12nmol/L (346ng/dL); TD is unlikely If TT is <12nmol/L (346ng/dL), proceed to step 2 Step 2: TT assay on serum from a second venous blood sample drawn between 08:00AM and noon after an interval of at least one week, together with: Serum LH (to distinguish primary and secondary TD) and prolactin In case of obese and older men, sex-hormone binding globulin (SHBG) Treatment of TD Treatment of sleep apnea, weight reduction, and discontinuation of opioid medication may result in increased testosterone synthesis. Before offering drug treatment, the physician must identify men who wish to maintain their fertility and testicular volume, as prescription of testosterone is highly ISSM Quick Reference Guide on Testosterone Deficiency for men 3

likely to supress spermatogenesis and fertility, and reduce testicular volume. Such men should be referred for specialist management. At the time of publication, preparations of testosterone are the only pharmacological treatments approved for the indication of TD, regardless of its cause. There are differences between testosterone preparations in route of delivery, ease of use, pharmacokinetics and cost. Choice of treatment should be agreed on with patients to respect their preferences and promote long-term compliance. Treatment monitoring Treatment effect on symptoms and inquiry about side effects should be made 3, 6, and 12 months after initiating TRT, and then annually thereafter. The following issues should be covered during a follow-up visit: Laboratory work-up: TT, hematocrit, lipid profile, PSA (men aged 40 and older). Clinical history: inquire about therapeutic and adverse effects; inquire about changes in general health and medication usage; review compliance with dosing and administration instructions. Physical examination: inspect body habitus for evidence of testosterone effect; assess weight/body mass index/waist circumference and blood pressure; inspect and palpate testes, noting any change in size and consistency; in men aged 40 and older, perform digital rectal examination of prostate; for transdermal TRT users, inspect application sites. The goal of TRT is to restore testosterone levels to the midnormal range and to alleviate the signs and symptoms associated with TD. Hematocrit, PSA, and lipids should remain within laboratory reference ranges; out-of-range results should be managed according to authoritative local guidelines. The absence of large-scale, long-term controlled studies with testosterone therapy precludes making definitive statements regarding TRT and cardiovascular risk. Equally, the weight of currently available evidence does not support the restriction of TRT, which, on balance, may benefit many men at risk of cardiovascular disease. TRT should not be given to men with prostate cancer except under specialist supervision. 4 ISSM Quick Reference Guide on Testosterone Deficiency for men

NEXT PAGE: Figure 1: Flow chart for the process of care for the assessment and management of testosterone deficiency in adult men Figure 2: Flow chart for the process of care for the assessment and management of testosterone deficiency in adult men wishing to maintain fertility ISSM Quick Reference Guide on Testosterone Deficiency for men 5

Figure 1: Flow chart for the process of care for the assessment and management of testosterone deficiency in adult men Erectile dysfunction, hypoactive sexual desire, osteoporosis, other potential symptoms or signs of TD or at-risk patient History, physical examination and Morning Total Testosterone (TT) Low or borderline low T; T<12nmol/l (346ng/dL) Normal T; T>12nmol/l (346ng/dL) Repeat TT + LH, SHBG, PRL No TD-seek other causes T 8-12nmol/l (231-346ng/dL) +/- SHBG, bother ++ TD if T<8nmol/l (<346ng/dL) Normal T; T>12nmol/l (<346ng/dL) High LH Low/Normal LH Exclude contraindications Investigate pituitary + other causes Reassess, consider referral or trial of TRT Trial of TRT Lifestyle modification No identifiable cause Identified cause Successful Monitor TT, FBC Failure Review diagnosis Manage cause 6 ISSM Quick Reference Guide on Testosterone Deficiency for men

Figure 2: Flow chart for the process of care for the assessment and management of testosterone deficiency in adult men wishing to maintain fertility Man with TD Signs and/or symptoms AND repeatedly low TT Assess possible contraindications or cautions related to TRT Hematocrit, prostate, others (incl. breast Ca, severe sleep apnoea, severe cardiac failure) If obese, lifestyle modification and weight loss exercise, low calorie diet ±medical/surgical intervention Desire to maintain fertility No desire to maintain fertility Stimulation of endogenous T secretion (if LH not elevated) specialist referral for treatment with?serms?hcg ± FSH TRT Follow-up at 3 and 6 months Signs and symptoms, weight, TT, Hct, PSA Not improved after 6 months Consider discontinuation Search for other causes/treatments Improved Continue 6 month follow-up including annual DRE after age 40 years ISSM Quick Reference Guide on Testosterone Deficiency for men 7

For more information ISSM Executive Office PO Box 94 1520 AB Wormerveer The Netherlands Phone: +31-75-6476372 Fax: +31-75-6476371 E-mail: secretariat@issm.info Internet: http://www.issm.info